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Abstract. Photoacoustic imaging (PAI) contributes to tumor diagnosis through the use of PAI probes that effec-
tively accumulate in tumors. Previously, we developed a symmetrical cyanine dye, IC7-1-Bu, which showed high
potential as a PAI probe because of its high tumor targeting ability and sufficient in vivo PA signal. However, IC7-
1-Bu lacks photostability for multiple laser irradiations, so we developed stabilized PAI probes using IC7-1-Bu as
a lead compound. We focused on the effect of singlet oxygen (1O2) generated by excited PAI probes on probe
degeneration. We introduced a triplet-state quencher (TSQ) moiety into IC7-1-Bu to quench 1O2 generation and
designed three IC-n-T derivatives with different linker lengths (n indicates linker length). The IC-n-T derivatives
emitted in vitro PA signals that were comparable to IC7-1-Bu and significantly reduced 1O2 generation while
showing improved photostability against multiple irradiations. Of the three derivatives evaluated, IC-5-T accu-
mulated in tumors effectively to allow clear PAI of tumors in vivo. Furthermore, the photostability of IC-5-T was
1.5-fold higher than that of IC7-1-Bu in in vivo sequential PAI. These results suggest that IC-5-T is a potential PAI
probe for in vivo sequential tumor imaging. © 2015 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.20.9
.096006]
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1 Introduction
Since the number of cancer cases continues to increase,1 the
development of noninvasive imaging methods to detect cancer
is very important for early diagnosis.2 Photoacoustic imaging
(PAI) using the PA effect of endogenous biomolecules or exog-
enous contrast agents has emerged as a new imaging technique
that has developed rapidly over recent years because PAI can
detect PA signals from depths of up to 5 cm with high contrast
and spatial resolution.3,4 Thus, the development of effective
PA contrast agents is urgently needed for noninvasive cancer
imaging.
Low molecular weight dyes with a maximum absorption
wavelength in the near-infrared (NIR) region used as PAI probes
would have a clear advantage over nanotechnology-based
contrast agents in terms of having simple preparation, cost-
effectiveness, and potentially low toxicity. Such dyes would
thus have various applications in clinical settings. In our pre-
vious report, we developed a symmetrical NIR cyanine dye
for use as a probe in fluorescence imaging of tumors5 and
preclinically evaluated its usefulness for cancer imaging with
PAI.6 This dye, IC7-1-Bu (2-(2-(3-(2-(3-butyl-1,1-dimethyl-1,3-
dihydro-2H-benz[e]indol-2-ylidene)ethylidene)-2-chlorocyclohex-
1-en-1-yl)vinyl)-3-butyl-1,1-dimethyl-1H-benz[e]indol-3-ium),
accumulated to high levels in mouse tumors after intravenous
injection using serum albumin as a drug carrier for tumor target-
ing and enabled clear tumor imaging with PAI. However, a
second laser irradiation for serial observation of dye biodistri-
bution greatly diminished the PA signals detected in tumors.
This finding differed from results for another fluorescence
imaging experiment using the same dye, likely because of the
high-energy laser pulses needed for PAI4 that could degrade
PAI probes. These results indicated that a high photostability of
PAI probes is needed for effective applications and that the pho-
tostability of IC7-1-Bu should be improved.
A PAI probe excited with a NIR pulse laser generates singlet
oxygen (1O2) from triplet oxygen (3O2) in a given region, which
could lead to PAI probe degeneration.7 Therefore, to improve its
photostability for serial tumor imaging studies, IC7-1-Bu could
be modified by introducing a chemical moiety that can function
as a triplet-state quencher (TSQ) that may reduce 1O2 generation
and improve dye photostability. In this study, we focused on a 4-
nitrobenzyl alcohol derivative as a usable TSQ moiety8 and syn-
thesized a series of IC7-1-Bu derivatives conjugated with a 4-
nitrobenzyl alcohol derivative (named IC-n-T derivatives, where
n represents the alkyl chain length, as shown in Fig. 1). We
evaluated the PA properties of these probes and their photo-
stability in in vitro experiments. We next investigated their use-
fulness as tumor imaging agents using tumor-bearing mice and
an in vivo PAI modality.
*Address all correspondence to: Hideo Saji, E-mail: hsaji@pharm.kyoto-u.ac.jp 1083-3668/2015/$25.00 © 2015 SPIE
Journal of Biomedical Optics 096006-1 September 2015 • Vol. 20(9)
Journal of Biomedical Optics 20(9), 096006 (September 2015)
2 Materials and Methods
2.1 Materials
All reagents were purchased from Wako Pure Chemical Indus-
tries, Ltd. (Osaka, Japan), Tokyo Chemical Industry Co., Ltd.
(Tokyo, Japan), or Nacalai Tesque Inc. (Kyoto, Japan) and
were used without further purification. For cell experiments,
Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from Nissui Pharmaceut-
ical Co., Ltd. (Tokyo, Japan) and Nichirei Co. (Tokyo, Japan),
respectively. D10001 was purchased from Research Diets, Inc.
(New Brunswick, New Jersey).
2.2 Instruments
1H-nuclear magnetic resonance (NMR) spectra were recorded
on a JEOL ECP-400 apparatus (JEOL Ltd., Tokyo, Japan).
Mass spectra and high-resolution mass spectra (HRMS)
were acquired on a Shimadzu LC-MS2010 EV spectrometer
(Shimadzu Co., Kyoto, Japan) and JEOL JMS-SX 102A QQ
spectrometer (JEOL Ltd.), respectively. UV-vis spectra were
measured using a UV-1800 spectrometer (Shimadzu Co.).
Fluorescence spectroscopy was performed with a Fluorolog-3
device equipped with a NIR sensitive photomultiplier detec-
tion system (∼1200 nm) (HORIBA Jobin Yvon Inc., Kyoto,




ylidene]anilinium chloride (2) and 3-butyl-1,1,2-trimethyl-1H-





Compound 4 (500 mg, 1.3 mmol) and anhydrous sodium acetate
(NaOAc, 125 mg, 1.5 mmol) were added to compound 2
(456 mg, 1.3 mmol), dissolved in ethanol (EtOH, 12 mL), and
the mixture was refluxed for 3 h. After completion of the reaction,
the mixture was cooled to room temperature and the solvent was
evaporated. The reaction mixture was partitioned between chloro-
form (CHCl3) and water (H2O), and the organic layer was sep-
arated, washed with brine, dried over anhydrous sodium sulfate
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Fig. 1 Synthesis of IC-n-T derivatives.
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(Na2SO4), and concentrated under vacuum. The residue was puri-
fied by column chromatography to obtain compound 5, which
was a dark-red solid (76 mg, 12%). 1H NMR (CDCl3) δ 8.74
(s, 1H), 8.08 to 7.83 (m, 4H), 7.55 to 7.37 (m, 6H), 7.23 to
7.20 (m, 2H), 3.01 (s, 1H), 2.63 (t, J ¼ 5.9, 2H), 1.99 to 1.42
(m, 18H), 1.03 (t, J ¼ 7.3, 3H): MS (ESI, pos) m∕z calcd. for
C33H36ClN2 (M+): 495, detected: 495.





1,1,2-Trimethyl-1H-benz[e]indole (1.1 g, 5.2 mmol) was added
to bromoalkanoic acid (15.5 mmol) dissolved in toluene (1.5
mL), and the mixture was refluxed for 12 h. The resulting pre-
cipitate was washed with tetrahydrofuran, ether, and CHCl3 and
then dried under vacuum. The product (compound 7) was used
for the next reaction without further purification. Compound 6
(0.061 mmol) was mixed with compound 5 (30 mg, 0.061
mmol) and NaOAc (6 mg, 0.072 mmol) in EtOH (600 μL),
and the mixture was refluxed for 3 h. After completion of
the reaction, the mixture was cooled to room temperature and
the solvent was evaporated. The reaction mixture was parti-
tioned between CHCl3 and H2O, and the organic layer was sep-
arated, washed with brine, dried over anhydrous Na2SO4, and
concentrated under vacuum. The residue was purified by col-




3-ium (7a). 7a was obtained from 3-bromopropionic acid as
a dark-green solid (21 mg, 43%). 1H NMR (CDCl3) δ 8.52 (d,
J ¼ 14 Hz, 1H), 8.42 (d, J ¼ 14 Hz, 1H), 8.13 (d, J ¼ 8.5 Hz,
2H), 7.98 to 7.92 (m, 4H), 7.63 to 7.60 (m, 2H),
7.54 to 7.32 (m, 4H), 6.51 (d, J ¼ 14 Hz, 1H), 6.05 (d, J ¼
14 Hz, 1H), 4.61 (t, J ¼ 6.6 Hz, 2H), 4.10 (t, J ¼ 7.4 Hz,
2H), 3.05 (t, J ¼ 6.6 Hz, 2H), 2.77 (t, J ¼ 5.3 Hz, 2H), 2.66
(t, J ¼ 5.3 Hz, 2H), 2.03 to 1.99 (m, 14H), 1.91 to 1.83 (m, 2H),
1.56-1.47 (m, 2H), 1.05 (t, J ¼ 7.3, 3H): MS (ESI, pos) m∕z




3-ium (7b). 7b was obtained from 5-bromovaleric
acid as a dark-green solid (15 mg, 30%). 1H NMR (CDCl3)
δ 8.53 (d, J ¼ 14 Hz, 1H), 8.38 (d, J ¼ 14 Hz, 1H), 8.14 to
8.11 (m, 2H), 7.99 to 7.91 (m, 4H), 7.65 to 7.59 (m, 2H),
7.53 to 7.31 (m, 4H), 6.46 (d, J ¼ 14 Hz, 1H), 6.02 (d, J ¼
14 Hz, 1H), 4.36 (t, J ¼ 7.5 Hz, 2H), 4.08 (t, J ¼ 7.4 Hz,
2H), 2.83 to 2.80 (m, 4H), 2.67 (t, J ¼ 5.9 Hz, 2H), 2.02 to
1.83 (m, 20H), 1.57 to 1.48 (m, 2H), 1.05 (t, J ¼ 7.3, 3H):





indol-3-ium (7c). 7c was obtained from 6-bromohexanoic
acid as a dark-green solid (17 mg, 33%). 1H NMR (CDCl3)
δ 8.52 (d, J ¼ 14 Hz, 1H), 8.41 (d, J ¼ 14 Hz, 1H), 8.13 (d,
J ¼ 8.5 Hz, 2H), 7.99 to 7.92 (m, 4H), 7.65 to 7.59 (m, 2H),
7.53 to 7.32 (m, 4H), 6.35 (d, J ¼ 14 Hz, 1H), 6.06 (d, J ¼
14 Hz, 1H), 4.25 (t, J ¼ 7.4 Hz, 2H), 4.10 (t, J ¼ 7.4 Hz,
2H), 2.76 (t, J ¼ 5.3 Hz, 2H), 2.68 (t, J ¼ 5.3 Hz, 2H),
2.57 (t, J ¼ 6.7, 2H), 2.07-1.92 (m, 20H), 1.89 to 1.81 (m,
4H), 1.61 (t, J ¼ 6.7, 3H): MS (ESI, pos) m∕z calcd. for
C48H53ClN2O2 (M+): 725, detected: 725.




1H-benz[e]indol-3-ium 9a to 9c
Compound 8 (1 equiv) was mixed with 4-nitrobenzylamine
hydrochloride (1 equiv) and N;N 0-dicyclohexylcarbodiimide
(DCC, 1.2 equiv) in N;N-dimethylformamide (130 to 260 μL),
and the mixture was stirred at room temperature for 1 day. After
completion of the reaction, the reaction mixture was partitioned
between CHCl3 and H2O and the organic layer was separated,
washed with brine, dried over anhydrous Na2SO4, and con-
centrated under vacuum. The residue was purified by column
chromatography and reverse phase-high performance liquid
chromatography (RP-HPLC) on a Cosmosil 5C18 column to
obtain compounds 9a to 9c. The mobile phase of RP-HPLC
was isocratic with 30% H2O [0.1% trifluoroacetic acid
(TFA)] and 70% methanol (MeOH, 0.1% TFA) at 0 to
5 min, followed by a gradient mobile phase going from 30%
H2O (0.1% TFA) and 70% MeOH (0.1% TFA) at 5 min to




propyl)-1H-benz[e]indol-3-ium (9a: IC-2-T). 9a was
obtained from compound 7a as a dark-green solid (1.2 mg,
8%). 1H NMR (CDCl3) δ 10.31 (bs, 1H), 8.52 (d, J ¼ 14 Hz,
1H), 8.35 (d, J ¼ 14 Hz, 1H), 8.12 (d, J ¼ 7.9 Hz, 2H), 7.96 to
7.90 (m, 6H), 7.70 to 7.28 (m, 8H), 6.55 (d, J ¼ 14 Hz, 1H),
5.96 (d, J ¼ 14 Hz, 1H), 4.67 (t, J ¼ 6.8 Hz, 2H), 4.44 (d, J ¼
5.8 Hz, 2H), 4.05 (t, J ¼ 7.5, 2H), 3.11 (t, J ¼ 6.8 Hz, 2H),
2.71 (t, J ¼ 5.9 Hz, 2H), 2.63 (t, J ¼ 5.9 Hz, 2H), 2.03-1.84
(m, 16H), 1.56-1.48 (m, 2H), 1.06 (t, J ¼ 7.3, 3H); MS
(ESI, pos) m∕z calcd. for C52H54ClN4O3 (M+): 817, detected:





pentyl)-1H-benz[e]indol-3-ium (9b: IC-4-T). 9b was
obtained from compound 7b as a dark-green solid (1.2 mg,
7.4%). 1H NMR (CDCl3) δ 9.45 (bs, 1H), 8.55 (d, J ¼ 14 Hz,
1H), 8.37 (d, J ¼ 14 Hz, 1H), 8.14 to 8.06 (m, 4H), 8.01 to 7.91
(m, 4H), 7.66 to 7.44 (m, 8H), 6.48 (d, J ¼ 14 Hz, 1H), 5.97 (d,
J ¼ 14 Hz, 1H), 4.55 (t, J ¼ 6.2 Hz, 2H), 4.44 (t, J ¼ 7.0 Hz,
2H), 4.06 (t, J ¼ 7.4, 2H), 2.81 (t, J ¼ 5.9 Hz, 2H), 2.72 (t,
J ¼ 6.5 Hz, 2H), 2.64 (t, J ¼ 5.9 Hz, 2H), 2.03-1.84 (m, 20H),
1.61-1.48 (m, 2H), 1.06 (t, J ¼ 7.3, 3H); MS (ESI, pos) m∕z
calcd. for C54H58ClN4O3 (M+): 845, detected: 845; HRMS
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hexyl)-1H-benz[e]indol-3-ium (9c: IC-5-T).. 9c was
obtained from compound 7c as a dark-green solid (1.0 mg,
13%). 1H NMR (CDCl3) δ 9.39 (bs, 1H), 8.53 (d, J ¼ 14 Hz,
1H), 8.39 (d, J ¼ 14 Hz, 1H), 8.14 to 8.08 (m, 4H), 7.99 to 7.92
(m, 4H), 7.65 to 7.30 (m, 8H), 6.33 (d, J ¼ 14 Hz, 1H), 6.01 (d,
J ¼ 14 Hz, 1H), 4.52 (t, J ¼ 6.0 Hz, 2H), 4.26 (t, J ¼ 7.3 Hz,
2H), 4.09 (t, J ¼ 7.5, 2H), 2.69 (t, J ¼ 6.0 Hz, 2H), 2.62 (t,
J ¼ 6.0 Hz, 2H), 2.47 (t, J ¼ 7.3 Hz, 2H), 2.03 to 1.78 (m,
20H), 1.63 to 1.49 (m, 4H), 1.06 (t, J ¼ 7.3, 3H); MS (ESI,
pos) m∕z calcd. for C55H60ClN4O3 (M+): 859, detected: 859;
HRMS (FAB) m∕z calcd. for C54H58ClN4O3 (M+): 859.43,
detected: 859.4354.
2.4 Photophysical Properties
For fluorescence spectroscopy analysis, dyes were dissolved in
phosphate-buffered saline (PBS, pH 7.4) containing 5 g∕dL
bovine serum albumin (BSA) (BSA solution, pH 7.4) at a con-
centration of 1 μM. Emission spectra were measured following
excitation at 823 nm. Absolute quantum yields were determined
using a Fluorolog-3 spectrofluorometer equipped with an inte-
grating sphere.
2.5 Evaluation of 1O2 Generation
Estimation of 1O2 generation by irradiation of dyes in PBS was
conducted as reported previously.9 Briefly, a mixture containing
180 μL PBS, 10 μL dye (200 μM) in dimethyl sulfoxide, and
10 μL singlet oxygen sensor green reagent (SOSGR, 200 μM)
in MeOH was irradiated by an 830-nm LED lamp with a power
density of 7.5 mW∕cm2. Fluorescence intensity of SOSGR at
525 nm was measured following excitation at 490 nm as a mon-
itor of 1O2 generation.
2.6 In Vitro Measurement of Photoacoustic Signals
In vitro PA signals from the dyes were measured as reported
previously.6,10 Briefly, the PA signal measurement system
setup consisted of an 830-nm wavelength pulsed light for
IC-n-T derivatives and IC7-1-Bu. The beams were generated
by a Model Titanium Sapphire Laser system (Lotis TII,
Minsk, Belarus) operating at 10 Hz with a 20-ns pulse duration.
A transducer Model V303 (Panametrics-NDT, Waltham,
Massachusetts; 1-MHz center frequency, 1-cm element size) and
ultrasonic preamplifier Model 5682 (Olympus Corporation,
Tokyo, Japan) collected the PA signal. A DPO3034 oscilloscope
(Tektronix Company, Tokyo, Japan) was used as a gauge
and light detection of the photodiode as a trigger. PA signals
for IC-n-T derivatives and IC7-1-Bu (0.4 to 10 μM) in BSA
solution were evaluated and normalized with irradiated laser
intensity.
In vitro photostability was evaluated with an Endra Life
Sciences Nexus 128 instrument. Dyes were dissolved in BSA
solution to give a concentration of 10 μM for the analysis.
Scans consisted of 60 angles with 25 pulses/angle and were per-
formed 10 times without any intervals. The excitation wave-
length was 830 nm, which was based on the absorption peak of
IC-n-T derivatives and IC7-1-Bu. Pulse laser intensity, pulse
width, and pulse frequency were 9 to 11 mJ, 7 ns, and 20 Hz,
respectively. PA images were constructed as a volumetric
rendering using OsiriX software. The reconstructed data were
analyzed using AMIDE and normalized with respect to irradi-
ated laser intensity. The normalized intensity (%) was calculated
as a percentage of photoacoustic intensity obtained for first time
measurements.
The ratio of intact to degraded IC-5-T and IC7-1-Bu after
photoirradiation was investigated with RP-HPLC. IC-5-T and
IC7-1-Bu were dissolved in PBS to give a concentration of
10 μM for the analysis and irradiated by an 830-nm LED
lamp with a power density of 7.5 mW∕cm2. After photoirradia-
tion, the samples were analyzed by RP-HPLC on a Cosmosil
5C18 column. The mobile phase of RP-HPLC was the same
as described for the general synthesis procedure for compounds
9a to 9c.
2.7 Cell Culture
The human cervix adenocarcinoma cell line HeLa was obtained
from American Type Culture Collection and was authenticated
with the Promega PowerPlex® 16 STR system in October 2012.
HeLa cells were maintained in DMEM supplemented with
10% heat-inactivated FBS, 1% penicillin and streptomycin in
a humidified atmosphere containing 5% CO2 at 37°C.
2.8 Protein-Binding Assay
Estimation of the dye binding site on albumin was conducted as
reported previously.5,11 Briefly, warfarin was used as a competi-
tive inhibitor of albumin binding site I. The inhibitor (0 and 3.8
mM) was incubated for 30 min at room temperature in BSA
solution. Immediately after the addition of the dyes (1 μM final
concentration), the fluorescence intensity was measured follow-
ing excitation at 823 nm and emission from 840 to 900 nm. The
normalized intensity (%) was calculated as a percentage of fluo-
rescence intensity obtained from samples that were not treated
with inhibitor.
Binding affinities of dyes to albumin were measured as
reported previously.12 Briefly, dyes (0 to 4 μM final concentra-
tion) were incubated with BSA (4 μM) for 30 min to equilibrate.
The binding affinities (Kb) of cyanine dyes to albumin can be
determined using the Hill equation expressed by Eq (1) for
a static quenching interaction.
EQ-TARGET;temp:intralink-;e001;326;245 log½ðF0 − FÞ∕F ¼ log Kb þ n log½dye; (1)
where n is the number of binding sites and F0 and F are the
fluorescence intensities of albumin tryptophans with or without
dyes, respectively.
2.9 In Vivo Imaging Study
Animal experiments were conducted in accordance with institu-
tional guidelines and approved by the Kyoto University Animal
Care Committee. Female nude mice (BALB/c nu∕nu 4-weeks
old), supplied by Japan SLC, Inc., were maintained under
a 12 h light∕12 h dark cycle and given free access to food
(D10001) and water. HeLa cells (2 × 106 cells in 100 μL of
PBS) were subcutaneously inoculated into the right hind legs
of mice and imaging studies were performed 14 days after
transplantation.
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For in vivo optical imaging studies performed 24 and 48 h after
intravenous administration of the IC-5-T derivative (10 nmol,
100 μL), tumor-bearing mice were anesthetized with 2.5% iso-
flurane gas in oxygen flow (1.5 L∕min) and imaged with a
Clairvivo® OPT apparatus (Shimadzu Co.) with a 785-nm single
laser. The power density was 1 mW∕cm2 for excitation13 and the
band-path filter for emission was 845∕55 nm. Clairvivo® OPT
measurement and display software version 2.6.0.1. (Shimadzu
Co.) were used for imaging analysis.
In vivo PAI was performed with an Endra Life Sciences
Nexus 128 instrument. A scan consisted of 120 angles with
50 pulses∕angle. The excitation wavelength was 830 nm,
which was based on the absorption peak of IC-n-T derivatives.
Pulse laser intensity, pulse width, and pulse frequency were
9 to 11 mJ, 7 ns, and 20 Hz, respectively. IC-n-T derivatives
(2.5 μmol∕kg) were injected into tumor-bearing mice (n ¼ 3)
via the tail vein and PA images acquired 24 and 48 h after injec-
tion following administration of 2.5% isoflurane for anesthesia.
PA images were constructed as a volumetric rendering using
OsiriX software. PA signal intensity was calculated from the val-
ues of volumetric rendering points and normalized with respect
to irradiated laser intensity. A region of interest-based analysis
was performed using AMIDE.
2.10 Statistical Analysis
Data are expressed as means standard deviation. Data were
analyzed with one-way factorial analysis of variance (ANOVA)
followed by the Tukey test, and values with p < 0.05 were con-
sidered significant.
3 Results
3.1 Synthesis of IC-n-T Derivatives
IC-n-T derivatives were synthesized from cyclohexanone and 1,
1, 2-trimethyl-1H-benz[e]indole following a similar synthetic
protocol for IC7-1-Bu, as shown in Fig. 1. Overall yields ranged
from 0.1% to 0.2%.
3.2 Photophysical Properties of IC-n-T Derivatives
The photophysical properties of the three IC-n-T derivatives in
BSA solution are summarized in Table 1. Each derivative
showed an absorption maximum at 830 nm and an emission
wavelength around 840 nm in BSA solution, which were both
similar to IC7-1-Bu.
The extinction coefficients of the IC-n-T derivatives were
around 2.0 × 105 M−1 cm−1, and the fluorescence quantum
yields around 0.05 were also similar to IC7-1-Bu. These results
indicate that IC-n-T derivatives could be useful PAI probes since
the nonradiative deactivation fraction of the absorbed light
energy is available for PA signal generation.
3.3 Evaluation of 1O2 Generation Following
Photoirradiation of IC-n-T Derivatives and
IC7-1-Bu
1O2 generation by photoirradiation of IC-n-T derivatives and
IC7-1-Bu was evaluated using SOSGR, a fluorescence indicator,
which reacts with 1O2 selectively, resulting in an increase in
525-nm emission.14 Figure 2 shows a significant decrease in
SOSGR fluorescence intensities in solutions containing IC-n-T
derivatives relative to the IC7-1-Bu solution. These results indi-
cate that IC-n-T derivatives decreased 1O2 generation by photo-
irradiation compared to IC7-1-Bu.
3.4 In Vitro PA Properties of IC-n-T Derivatives and
IC7-1-Bu
We then measured the PA signal of IC-n-T derivatives in vitro to
compare them with those of IC7-1-Bu. Figure 3(a) illustrates
the correlation of PA signals with the dye concentration in the
cuvettes. All three IC-n-T derivatives in BSA solution showed
PA signals that were comparable to that of IC7-1-Bu.
The PA signals of the IC-n-T derivatives and IC7-1-Bu were
measured 10 times to obtain sequential PA signal profiles, as
shown in Fig. 3(b). IC-n-T derivatives showed smaller decreases
in PA signals compared to IC7-1-Bu.
Table 1 Photophysical properties of IC-n-T derivatives and IC7-1-Bu
in bovine serum albumin solution.
λabs
a (nm) λem
b (nm) Φc εd (M−1cm−1)
IC-2-T 830 845 0.04 1.8 × 105
IC-4-T 830 845 0.04 2.3 × 105
IC-5-T 830 843 0.05 2.1 × 105





Fig. 2 Evaluation of 1O2 generation by photoirradiation of IC-n-T
derivatives and IC7-1-Bu. Normalized intensities plotted against the
fluence. Comparisons were performed with one-way analysis of vari-
ance (ANOVA) followed by the Tukey test (*P < 0.05 versus IC7-1-Bu
and dye (−), †P < 0.05 versus IC7-1-Bu). Data are means
standard deviation (SD) of three independent experiments.
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The RP-HPLC analysis of photoirradiated IC7-1-Bu and
IC-5-T is shown in Figs. 3(c) and 3(d), respectively. While
38 2% of IC-5-Twas intact after 20 mJ∕cm2 photoirradiation,
only 10 4% of intact IC7-1-Bu remained.
3.5 Protein-Binding Assay
The albumin-binding affinities of the dyes were measured to
estimate if IC-n-T derivatives could be delivered to tumor sites
in vivo using serum albumin as a drug delivery carrier as was
done for an earlier study using IC7-1-Bu.5 IC-n-T derivatives
also bound to albumin at the warfarin binding site (Fig. 4) with
IC-5-T having moderate albumin binding. Meanwhile, the other
IC-n-T derivatives had lower albumin binding affinities relative
to IC7-1-Bu (Table 2).
3.6 In Vivo Imaging Study
Fluorescence images of tumor-bearing mice after administration
of IC-n-T derivatives and IC7-1-Bu clearly depicted tumors
(Fig. 5). After administration, IC-5-T showed higher fluores-
cence intensity in the tumor region than IC-2-T and IC-4-T.
The percentage of IC-n-T derivative fluorescence intensity
that remained in the tumor region 2 days after intravenous ad-
ministration was comparable to that of IC7-1-Bu (0.84 0.05,
0.86 0.03, 1.00 0.03, and 1.04 0.02 for IC-2-T, IC-4-T,
IC-5-T, and IC7-1-Bu, respectively).
In vivo PAI of tumor-bearing mice after administration of IC-
5-T and IC7-1-Bu also clearly depicted tumors. The percentage
of the PA signal at the tumor region 2 days relative to 1 day after
intravenous administration was 89% for IC-5-T and 61% for
IC7-1-Bu (Fig. 6).
Fig. 3 In vitro photoacoustic (PA) properties of IC-n-T derivatives and IC7-1-Bu. (a) Single-time meas-
urement of IC-n-T derivatives and IC7-1-Bu PA signals. PA signals were plotted against the concentra-
tions of IC-n-T derivatives and IC7-1-Bu. (b) Multiple time measurement of IC-n-T derivatives and IC7-1-
Bu PA signals. PA signals were plotted against irradiation times. Data are means SD of three inde-
pendent experiments. (c) RP-HPLC analysis of photoirradiation of IC7-1-Bu. Arrow indicates intact IC7-1-
Bu. (d) RP-HPLC analysis of photoirradiated IC-5-T. Arrows indicate intact IC-5-T.
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4 Discussion
In this study, we designed and synthesized IC-n-T derivatives to
improve the photostability of IC7-1-Bu for use in in vivo
sequential tumor imaging with PAI. An in vitro analysis indi-
cated the potential of IC-n-T derivatives for further animal
experiments because they showed improved photostabilities
that were likely due to a significant decrease in 1O2 levels
generated by laser irradiation. Furthermore, the derivatives
retained PA capacities that were comparable to IC7-1-Bu and
a maximum absorbance wavelength in the NIR. In in vivo PAI
studies, IC-5-T also clearly depicted tumors 1 and 2 days after
intravenous injection, which indicates the successful improve-
ment in photostability in vivo. Together, these results suggest
that IC-5-T is a promising probe for in vivo sequential cancer
imaging with PAI.
PAI has shown great promise for the early detection of cancer
due to its ability to provide functional and molecular informa-
tion with high resolution at clinically relevant depths, although
exogenous contrast agents for in vivo PAI are required to
increase imaging contrast and depth.3,4 Considering the in vivo
PAI of tumors, molecular probes should have the following
characteristics: (1) photon absorption at a wavelength of 700
to 900 nm (NIR region) for high tissue permeability; (2) efficient
PA signal generation; (3) high levels of probe accumulation in
tumor tissues that compensate for the relatively low intrinsic
sensitivity of PAI relative to optical imaging;2,15 and (4) photo-
stability following exposure to the high-energy laser pulses
delivered during PAI.4 In fact, our previous report showed
that IC7-1-Bu has met requirements (1), (2) and (3), and has
clearly depicted tumors in in vivo PAI experiments with single
laser irradiation.6 In addition, the improved photostability of
IC7-1-Bu should promote the usefulness of IC7-1-Bu for wider
applications such as in vivo follow-up experiments using an
identical animal to evaluate the efficacy of treatment drugs or
operations by in vivo sequential PAI.
We selected the TSQ moiety for introduction into the IC7-1-
Bu structure to improve photostability because this group should
quench dye degeneration induced by the 1O2 generated from
energy transfer reactions between ground state triplet oxygen
and triplet state dyes.7 Indeed, the photostability of fluorescent
Table 2 Albumin-binding affinities of IC-n-T derivatives.
IC-2-T IC-4-T IC-5-T IC7-1-Bu
K b (×105) 7.9 10 13 25
Fig. 4 Estimation of IC-n-T derivative protein binding. Data are
means SD of three independent experiments. Comparisons were
performed with one-way ANOVA followed by a Tukey test (*P < 0.01).
Fig. 5 In vivo optical imaging of IC-n-T derivatives and IC7-1-Bu
using HeLa cell xenograft mice. Fluorescence images of HeLa cell
xenograft mice 1 and 2 days after intravenous dye administration.
Arrows indicate the tumor.
Fig. 6 In vivo PAI of IC-5-T using HeLa cell xenograft mice.
Photoacoustic images of HeLa cell xenograft mice 1 and 2 days
after intravenous administration of IC-5-T.
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compounds was reportedly improved in buffer solutions con-
taining antioxidants and TSQ at micro- to millimolar concentra-
tions,16,17 and the direct introduction of a moiety that functions
as a photostabilizer into the fluorescent dye structure could fur-
ther improve the photostability.8 Among several TSQs that have
been described, we adopted 4-nitrobenzyl alcohol derivatives
because they do not require linkers for conjugation and have
a small molecular size such that the TSQ should have minimal
effects on important characteristics of the mother compound.
Considering the site of TSQ moiety conjugation to IC7-1-Bu,
a chloro group at the fluorophore center could be a candidate
for the substitution, but this group can cause a large spectral
shift in absorbance.18,19 Our preliminary experiments also sug-
gested that a compound substituted at the center of the fluoro-
phore can change the optical properties dramatically. On the
other hand, cyanine dye side chains are independent from
the fluorophore and do not affect their optical properties.5,20
Hence, we decided to introduce the 4-nitrobenzyl alcohol struc-
ture onto one of the IC7-1-Bu side chains. The results show that
this drug design strategy functions well in terms of having a high
capacity to quench 1O2 generation and negligible effects on
optical properties.
Albumin has been recognized as a useful drug delivery car-
rier to effectively deliver therapeutic and diagnostic agents to
tumor tissues via the enhanced permeability and retention
effect.21,22 As we previously reported, after intravenous admin-
istration, IC7-1-Bu effectively accumulated in tumor tissues
when serum albumin was used as a drug delivery carrier.5
That study also showed that the side chain lengths of symmet-
rical cyanine dyes alter the binding affinity of the dyes to albu-
min and in turn the tumor targeting activity in animals. A
preliminary computer simulation of IC7-1-Bu and albumin
binding using the molecular modeling software MOE version
2010.10 also implied that the modification of a single alkyl
chain of IC7-1-Bu would not significantly affect the albumin
binding of this probe. On this basis, the length of asymmetrical
cyanine side chains is important, thus we designed a series of
IC-n-T derivatives with a butyl chain on one side and an alkyl
chain with several different lengths ranging from two (IC-2-T)
to five carbons (IC-5-T) on another side with the expectation that
probe biodistributions would be altered in a similar fashion to
that seen in our previous study.23 While the asymmetric cyanine
dye IC-n-T derivatives showed slightly lower albumin affinities
than IC7-1-Bu, IC-5-T showed moderate fluorescence accumu-
lation in tumors. This implies the contribution of serum albumin
as a drug delivery carrier for IC-n-T derivatives like IC7-1-Bu,
and contrary to our expectation, steric interference by the intro-
duced moiety may have affected the albumin binding of IC-n-T
derivatives. Since IC-5-T showed the highest albumin affinity
among the IC-n-T derivatives, linker chains with more than five
carbons may be useful to evaluate this finding. Nevertheless, it
should be stressed that IC-5-T retained tumor targeting capacity
at levels that were sufficient to advance in vivo PAI experiments.
In surgical treatment of tumors, incomplete resection often
causes tumor recurrence and reduction of survival rates, thus
a real-time imaging method that helps the surgeon to define
microcancer locations is urgently needed to treat cancer in its
earliest stages. While in vivo fluorescence imaging can be used
for this purpose,24,25 in vivo PAI has a great advantage in terms
of tissue permeability and can be used to create tomographic
images that are highly quantitative. These qualities suggest that
PAI-based image-guided surgery (PAI-IGS)26 may have high
potential as an effective tool in early cancer diagnosis and treat-
ment. Since IGS naturally requires sequential imaging of tumor
sites of interest during the operation, PAI probes for IGS should
be photostable in the face of sequential laser irradiations. In
this context, the IC-5-T probe developed in this study showed
reliable stability at up to 20mJ∕cm2 of laser irradiation, which is
recognized as the maximal limit for irradiation of human skin
without any harmful effects.27 Thus, IC-5-T could be a lead
compound for PAI-IGS applications.
An ideal PAI probe should be highly stable against sequential
high-energy laser irradiation.4,28 While IC-5-T showed high
photostability in addition to unique characteristics as a tumor
imaging probe with a low molecular weight, further improve-
ment in IC-5-T photostability would be required to obtain
quantitative and accurate tomographic images of tumor. Since
nitrobenzyl groups can be degraded enzymatically,29 the intro-
duction of other TSQ moieties to IC7-1-Bu may be effective
to develop other photostabilized dyes. In addition, cyanine
dyes can reductively react with nucleophilic reagents such as
primary amine and thiol compounds, which may alter their
chemical forms and optical properties.7 Indeed, cyanine dyes
were reported to react with endogenously produced biomole-
cules, such as hydrogen sulfide and histamine, leading to
altered absorption spectra.18,19 Therefore, probe derivatization
approaches, such as polyfluorination, could decrease the oxida-
tion potential to prevent such reduction reactions and may
improve cyanine dye photostability.30 However, since further
derivatization might reduce the probe’s albumin binding affinity
and tumor targeting ability, precise drug design that simultane-
ously maintains high photostability and tumor targeting capacity
is required to develop ideal PAI probes.
In conclusion, we developed a novel TSQ-conjugated
asymmetric cyanine dye, IC-5-T, which shows improved photo-
stability for use in in vivo sequential PAI of tumors. IC-5-T
demonstrated adequate PA signal generation, improved photo-
stability through reduced 1O2 generation, high tumor accumu-
lation, and a maximum absorption peak in the NIR. These
qualities suggest that IC-5-T has potential applications as an
in vivo PAI probe for tumor imaging.
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